HRT Financial’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

HRT Financial’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-377,431	Closed	-$15.4M	–	3366
2024 Q2	$15.4M	Buy	377,431 +320,816	+567%	+$13.4M	0.09%	178
2024 Q1	$2.39M	Sell	56,615 -25,711	-31%	-$1.08M	0.01%	504
2023 Q4	$3.49M	Buy	+82,326	New	+$2.37M	0.03%	424
2022 Q1	–	Sell	-29,088	Closed	-$943K	–	4051
2021 Q4	$943K	Buy	+29,088	New	+$1.03M	0.01%	1197
2021 Q2	–	Sell	-33,368	Closed	-$458K	–	3682
2021 Q1	$458K	Buy	+33,368	New	+$488K	﹤0.01%	1856

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HRT Financial's CERE Position: Q3 2024 in Review

HRT Financial sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 377,431 shares — an estimated $15.4M sold.

HRT Financial first reported a position in CERE in Q1 2021 and held it in 5 quarters. The position peaked at $15.4M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

HRT Financial reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
HRT Financial sold 377,431 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $15.4M.
HRT Financial first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
HRT Financial's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $15.4M in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on HRT Financial's 13F filing for Q3 2024, filed 12 Nov 2024.